Современные представления о CAR T-клеточной терапии

Современные представления о CAR T-клеточной терапии

Автор: Кувшинов А. Ю., Волошин С. В., Кузяева А. А., Шуваев В. А., Михалева М. А., Мартынкевич И. С., Чечеткин А. В., Бессмельцев С. С.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Обзор литературы

Статья в выпуске: 2 т.15, 2019 года.

Бесплатный доступ

Адоптивная иммунотерапия является одним из признанных современныхметодов лечения онкологических заболеваний,основанном на достижениях генетики, молекулярной биологии и иммунологии, цельюкоторого является восстановление нормального функционирования противоопухолевогоответа. В основу данного вида терапии положено создание опухоль-специфичных цитотоксических лимфоцитов, экспрессирующиххимерный антигенный рецептор (chimericantigen receptor, CAR). Из экспериментальнойтехнологии лечение онкологических заболеваний CAR T-клетками превращается в быстроразвивающийся подход к терапии с более чем500 зарегистрированными клиническими исследованиями при гематологических новообразованиях и солидных опухолях. В статьепредставлено описание биотехнологии, результаты клинических исследований, обсуждениепобочных эффектов и проблем появления резистентности опухолей, а также рассмотреныперспективы дальнейшего развития и внедрения в рутинную клиническую практику CART-клеточной терапии.

Еще

Адоптивная иммунотерапия, химерный антигенный рецептор, cart-клетка, онкогематология

Короткий адрес: https://sciup.org/170172533

IDR: 170172533

Список литературы Современные представления о CAR T-клеточной терапии

  • Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of cellular Immunotherapy. 2016;2:59-68.
  • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-70.
  • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3:991-8.
  • ShankaranV, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2011;410:1107-11.
  • Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci Unit States Am. 1989;86(24):10024-8.
  • Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264.
  • Wen Si, Cheng Li, Ping Wei. Synthetic immunology: T-cell engeneering and adoptive immunotherapy. Synthetic and Systems Biotechnology.2018;3: 179-85.
  • Chmielewski M, Abken H. Trucks: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15: 1145-54.
  • Antonana-Vidosola A, Perez-Amill L, Sune G, Castella M, Najjar A, Lozano E, Urbano-Ispizua A, Martin-Antonio B. BCMA CAR T-cell immunotherapy beyond myeloma: a novel target to fight B-cell non-Hodgkin lymphoma. 1st European CAR T-cell meeting, 14-16 February 2019, Paris. PI17/01043.
  • Perez-Amill L, Sune G, Antonana-Vidosola A, Najjar A, Castella M, Lozano E, Urbano-Ispizua A, Martin-Antonio B. Pre-clinical evaluation of murine versus humanized BCMA-chimeric antigen receptor modified T cells (ARI2) for Multiple Myeloma treatment. 1st European CAR T-cell meeting, 14-16 February 2019, Paris. PI17/01043, PI14/00798.
  • Leivas A, Valeri A, Rio P, Garcia-Ortiz A, Pacello ML, Perez-Martinez A, Lee D, Martinez-Lopez J. NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells. 1st European CAR T-cell meeting, 14-16 February 2019, Paris.
  • Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest.2016;126(8):3036-52.
  • Bister A, Haist C, Schulte E, Scheckenbach K, Hanenberg H, Gattermann N, Wiek C. Dual targeting to reduce on-target off-tumor toxicities in CAR T-cell therapy for mantle cell lymphoma. 1st European CAR T-cell meeting, 14-16 February 2019, Paris.
  • Grigor EJM, Fergusson D, Kekre N, et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis, Transfusion Medicine Reviews. 2019. https://doi. org/10.1016/ j. tmrv.2019.01.005.
  • Olweus J. Manufacture of CAR-T cells in the body. Nature Biotechnology.2017;35:520-1.
  • Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR T-cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceutica Sinica B. 2018;8(4):539-551.
  • Li Y, Huo Y, Yu L et al. Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues, Engineering. 2019. https://doi. org/10.1016/j. eng.2018.12.003.
  • Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews. 2019. https://doi. org/10.1016/j. blre.2018.11.002.
  • Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol Aug. 2018;36(22):2267-80.
  • Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130:2594-602.
  • Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-Label phase I trial. Clin Cancer Res. 2017;23:1156-66.
  • Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462-71.
  • Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561-9.
  • Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6.
  • Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor- modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33:1688-96.
  • Grigor EJM, Fergusson D, Kekre N, et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfusion Medicine Reviews. 2019. https://doi. org/10.1016/ j. tmrv.2019.01.005.
  • Novartis (2017) Prescribing Information (KymriahH). Available at: https://www. pharma. us. novartis. com/ sites/www. pharma. us. novartis. com/files/kymriah. pdf
  • Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48.
  • Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545-54.
  • YescartaH (2017) Prescribing Information. Available at: https://www. fda. gov/downloads/ BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/ UCM581226. pdf
  • Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-44.
  • Neelapu SS, Tummala S, Kebriaei P, Wierda W, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Rev Clin Oncol. 2018; 15: 47-62.
  • Shank BR. Management of CAR T-cell Adverse Effects in hematological malignancies. HOPA Annual meeting. 2018 March.
  • Ellard R, 1st European CAR T-cell meeting, 14-16 February 2019, Paris.
  • Vickers E. What is driving CARs into the spotlight?-the science simplified. 1st European CAR T-cell meeting, 14-16 February 2019, Paris.
Еще
Статья обзорная
SciUp 2024 © 2024 ©